Insider · CIK 0001723092
Thomas Civik
Files at PYXS (Pyxis Oncology, Inc.), RPTX (Repare Therapeutics Inc.). First filing -, latest -.
Thomas Civik files SEC Form 4 as CEO, chair and director at PYXS (Pyxis Oncology, Inc.), and also at RPTX (Repare Therapeutics Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Thomas Civik has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 4, 2026 | PYXS Pyxis Oncology, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +2,503,050 | $0.00 | $0 | 2,503,050 | 35 d ago |
| Feb 3, 2026 | PYXS Pyxis Oncology, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +690,131 | $0.00 | $0 | 690,131 | Feb 5, 2026 |
| Jan 28, 2026 | RPTX Repare Therapeutics Inc. | DDisposition to issuer Common Shares | -7,500 | - | - | 0 | Jan 28, 2026 |
| Mar 31, 2025 | PYXS Pyxis Oncology, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +36,979 | $0.98 | $36k | 36,979 | Apr 2, 2025 |
Questions about Thomas Civik
Answered from the filings on this page, as of the latest one.
Is Thomas Civik buying or selling?
Thomas Civik has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Thomas Civik's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Thomas Civik has 0.
Where does Thomas Civik file Form 4?
Thomas Civik has filed Form 4 at PYXS (Pyxis Oncology, Inc.) as Interim CEO; RPTX (Repare Therapeutics Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.